Suppr超能文献

新冠病毒疾病19(COVID-19)疫苗首剂接种与未接种疫苗对长期新冠症状的疗效:基于ComPaRe电子队列的目标试验模拟

Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of with long covid: target trial emulation based on ComPaRe e-cohort.

作者信息

Tran Viet-Thi, Perrodeau Elodie, Saldanha Julia, Pane Isabelle, Ravaud Philippe

机构信息

Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004 Paris, France.

Centre d'Epidémiologie Clinique, AP-HP, Hôpital Hôtel Dieu, F-75004 Paris, France.

出版信息

BMJ Med. 2023 Feb 1;2(1):e000229. doi: 10.1136/bmjmed-2022-000229. eCollection 2023.

Abstract

OBJECTIVE

To evaluate the effect of covid-19 vaccination on the severity of symptoms in patients with long covid.

DESIGN

Target trial emulation based on ComPaRe e-cohort.

DATA SOURCE

ComPaRe long covid cohort, a nationwide e-cohort (ie, a cohort where recruitment and follow-up are performed online) of patients with long covid, in France.

METHODS

Adult patients (aged ≥18 years) enrolled in the ComPaRe cohort before 1 May 2021 were included in the study if they reported a confirmed or suspected SARS-CoV-2 infection, symptoms persistent for >3 weeks after onset, and at least one symptom attributable to long covid at baseline. Patients who received a first covid-19 vaccine injection were matched with an unvaccinated control group in a 1:1 ratio according to their propensity scores. Number of long covid symptoms, rate of complete remission of long covid, and proportion of patients reporting an unacceptable symptom state at 120 days were recorded.

RESULTS

910 patients were included in the analyses (455 in the vaccinated group and 455 in the control group). By 120 days, vaccination had reduced the number of long covid symptoms (mean 13.0 (standard deviation 9.4) in the vaccinated group 14.8 (9.8) in the control group; mean difference -1.8, 95% confidence interval -3.0 to -0.5) and doubled the rate of patients in remission (16.6% 7.5%, hazard ratio 1.93, 95% confidence interval 1.18 to 3.14). Vaccination reduced the effect of long covid on patients' lives (mean score on the impact tool 24.3 (standard deviation 16.7) 27.6 (16.7); mean difference -3.3, 95% confidence interval -5.7 to -1.0) and the proportion of patients with an unacceptable symptom state (38.9% 46.4%, risk difference -7.4%, 95% confidence interval -14.5% to -0.3%). In the vaccinated group, two (0.4%) patients reported serious adverse events requiring admission to hospital.

CONCLUSION

In this study, covid-19 vaccination reduced the severity of symptoms and the effect of long covid on patients' social, professional, and family lives at 120 days in those with persistent symptoms of infection.

摘要

目的

评估2019冠状病毒病(COVID-19)疫苗接种对长期新冠患者症状严重程度的影响。

设计

基于ComPaRe电子队列的目标试验模拟。

数据来源

ComPaRe长期新冠队列,这是法国一个针对长期新冠患者的全国性电子队列(即通过在线方式进行招募和随访的队列)。

方法

纳入2021年5月1日前登记到ComPaRe队列中的成年患者(年龄≥18岁),这些患者需报告确诊或疑似的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染、发病后持续超过3周的症状,以及基线时至少一种可归因于长期新冠的症状。根据倾向得分,将接受第一剂COVID-19疫苗注射的患者与未接种疫苗的对照组按1:1的比例进行匹配。记录长期新冠症状的数量、长期新冠完全缓解率,以及在120天时报告不可接受症状状态的患者比例。

结果

910名患者纳入分析(接种疫苗组455名,对照组455名)。到120天时,接种疫苗减少了长期新冠症状的数量(接种疫苗组平均为13.0(标准差9.4),对照组为14.8(9.8);平均差值-1.8,95%置信区间-3.0至-0.5),并使缓解患者的比例增加了一倍(16.6%对7.5%,风险比1.93,95%置信区间1.18至3.14)。接种疫苗减轻了长期新冠对患者生活的影响(影响工具的平均得分24.3(标准差16.7)对27.6(16.7);平均差值-3.3,95%置信区间-5.7至-1.0),以及处于不可接受症状状态的患者比例(38.9%对46.4%,风险差值-7.4%,95%置信区间-14.5%至-0.3%)。在接种疫苗组中,有两名(0.4%)患者报告了需要住院治疗的严重不良事件。

结论

在本研究中,对于有持续感染症状的患者,COVID-19疫苗接种在120天时降低了症状严重程度以及长期新冠对患者社会、职业和家庭生活的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7049/9978748/3e02bc1bb327/bmjmed-2022-000229f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验